当前位置:药药网 / 数据中心 / 儿科标签更改电子表格2021
Opana
儿科标签批准日期
2019/10/25 0:00:00
特定指示/秒
Postoperative pain
标签更改摘要
- Safety and effectiveness for pediatric patients, 0 to 17 years, have not been established.
- An open-label study was conducted in 58 pediatric patients 12 years and older with postoperative pain. Efficacy was not demonstrated in this population treated with doses expected to be comparable to effective starting doses in adults.
- Pharmacokinetic results demonstrated that treatment with Opana tablets resulted in substantially higher systemic exposures to oxymorphone in 2 out of 24 patients.
- Not recommended for use in the pediatric population.
- Postmarketing study.